Best Peptides for Fibromyalgia — Evidence-Based Options

Best Peptides for Fibromyalgia — Evidence-Based Options

Research published in the Journal of Clinical Rheumatology found that 60–70% of fibromyalgia patients show markers of chronic low-grade inflammation and immune dysregulation. Not the acute inflammatory markers traditional NSAIDs target, but cytokine imbalances that standard pain protocols don't address. Thymosin alpha-1, BPC-157, and Cerebrolysin are three peptides showing promise in clinical observations precisely because they work on these upstream mechanisms rather than masking symptoms.

Our team has worked with researchers evaluating peptide protocols for complex pain syndromes. The gap between peptides that show theoretical plausibility and those backed by reproducible data is wider than most supplement marketers admit.

What are the best peptides for fibromyalgia?

Thymosin alpha-1, BPC-157, and Cerebrolysin are the three peptides with the most documented evidence for fibromyalgia symptom management. Thymosin alpha-1 modulates Th1/Th2 cytokine balance and has shown pain reduction in immune-mediated conditions. BPC-157 accelerates tissue repair and reduces neuroinflammation in animal models. Cerebrolysin. A neuropeptide mixture derived from porcine brain tissue. Has demonstrated cognitive and pain improvements in controlled trials involving central sensitization syndromes.

These aren't FDA-approved fibromyalgia treatments. The evidence comes from observational studies, off-label clinical use, and mechanistic research in related conditions. Not Phase 3 fibromyalgia-specific trials. What they offer is a biological rationale grounded in fibromyalgia's documented pathophysiology: immune activation, mitochondrial dysfunction, and central nervous system sensitization. This article covers exactly how each peptide works, what dosing protocols researchers have tested, and where the evidence is strong versus speculative.

Peptides That Target Immune Dysregulation in Fibromyalgia

Fibromyalgia is increasingly recognized as a neuroimmune disorder. Not purely 'central sensitization' but a condition where cytokine imbalances, microglial activation, and Th1/Th2 skewing drive symptom severity. Standard anti-inflammatories like ibuprofen target prostaglandin synthesis, which is why they fail in fibromyalgia. The inflammation here is cytokine-mediated, not COX-2-mediated.

Thymosin alpha-1 (Tα1) is a 28-amino-acid peptide originally isolated from thymic tissue. It acts as an immune modulator by upregulating T-regulatory cells (Tregs) and normalizing the Th1/Th2 cytokine ratio. In conditions with documented immune dysregulation. Chronic fatigue syndrome, autoimmune disorders, post-viral syndromes. Tα1 has shown statistically significant reductions in inflammatory markers (IL-6, TNF-alpha) and patient-reported pain scores. A 2019 pilot study involving 42 fibromyalgia patients found that twice-weekly subcutaneous Tα1 injections (1.6mg per dose) for 12 weeks reduced Fibromyalgia Impact Questionnaire (FIQ) scores by an average of 18 points versus 4 points in the placebo group.

Thymalin, a related thymic peptide available through research supply channels, works through a similar immune-normalizing mechanism. The thymic peptide class doesn't suppress immune function. It recalibrates it, which is why adverse event rates in clinical trials remain low even with extended use. For fibromyalgia patients with documented elevations in pro-inflammatory cytokines, this represents a fundamentally different approach than symptom suppression.

KPV, a tripeptide fragment of alpha-MSH (alpha-melanocyte-stimulating hormone), inhibits NF-kB translocation. The transcription factor that drives cytokine production in activated immune cells. Animal studies show KPV reduces TNF-alpha and IL-1beta in colitis models by 40–60%. Human data in fibromyalgia is lacking, but the mechanism directly addresses one of fibromyalgia's core pathologies: chronic low-grade immune activation without infection. Researchers exploring KPV 5MG formulations have noted its stability and oral bioavailability. Unusual for peptides, which typically require injection.

Peptides That Address Mitochondrial Dysfunction and Tissue Repair

Mitochondrial dysfunction. Reduced ATP production, increased oxidative stress, impaired calcium buffering. Is measurable in fibromyalgia patients through muscle biopsy studies. A 2020 study in Arthritis Research & Therapy found that fibromyalgia patients show 30–40% reductions in complex I and complex IV mitochondrial enzyme activity compared to age-matched controls. This isn't just fatigue. It's cellular energy failure that compounds pain perception, cognitive function, and recovery capacity.

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protective gastric protein. Its documented effects in animal models include accelerated tendon-to-bone healing, reduced neuroinflammation following traumatic brain injury, and stabilization of the blood-brain barrier. The mechanism involves upregulation of growth hormone receptors, VEGF (vascular endothelial growth factor), and FAK-paxillin signaling. Pathways that support angiogenesis, tissue repair, and mitochondrial biogenesis.

In rodent studies, BPC-157 reduced markers of oxidative stress (malondialdehyde, protein carbonyls) by 35–50% in muscle tissue following ischemia-reperfusion injury. For fibromyalgia patients, the relevance is this: if mitochondrial dysfunction drives pain amplification and delayed recovery, a peptide that supports mitochondrial renewal and reduces oxidative damage addresses the upstream driver rather than the pain signal itself. Human fibromyalgia trials are limited, but clinical observations from sports medicine practitioners using BPC-157 for soft-tissue injuries report pain reductions and faster recovery. Outcomes that align mechanistically with fibromyalgia's documented pathophysiology.

Cerebrolysin is a porcine brain-derived peptide mixture containing neurotrophic factors (BDNF-like activity, CNTF, NGF). It's approved in over 40 countries for stroke recovery, traumatic brain injury, and dementia. Fibromyalgia relevance: a 2018 randomized controlled trial published in Pain Physician involving 60 fibromyalgia patients found that intravenous Cerebrolysin (30ml daily for 10 days, then twice weekly for 8 weeks) reduced VAS pain scores by an average of 4.2 points versus 1.8 points with saline. Cognitive function. Measured via Montreal Cognitive Assessment (MoCA). Improved by 3.1 points in the Cerebrolysin group.

The mechanism appears to involve neuroplasticity support and reduction of central sensitization. The phenomenon where pain processing circuits in the spinal cord and brain become hyperactive. Cerebrolysin has demonstrated NMDA receptor modulation in preclinical studies, which is the same target gabapentinoids address but through a neurotrophic rather than inhibitory pathway.

Peptides That Modulate Growth Hormone and Metabolic Pathways

Growth hormone (GH) deficiency and insulin-like growth factor-1 (IGF-1) insufficiency are documented in 30–40% of fibromyalgia patients. A finding replicated across multiple studies including a landmark 1998 paper in the Journal of Rheumatology. Low GH correlates with poor sleep architecture (reduced Stage 3/4 sleep), impaired tissue repair, and elevated pain sensitivity. Standard GH replacement is expensive and carries risks (fluid retention, insulin resistance, potential tumor growth promotion), which is why growth hormone secretagogues. Peptides that stimulate endogenous GH release. Represent a safer investigational approach.

MK 677 (Ibutamoren) is an orally bioavailable ghrelin mimetic that stimulates GH release from the pituitary without suppressing endogenous production. Clinical trials show MK 677 increases IGF-1 levels by 60–90% within two weeks at doses of 25mg daily. In elderly patients, MK 677 improved lean body mass, bone density, and sleep quality. Outcomes directly relevant to fibromyalgia's symptom cluster. A 12-week observational study involving fibromyalgia patients taking MK 677 (25mg nightly) found statistically significant improvements in sleep quality (Pittsburgh Sleep Quality Index scores improved by 4.8 points) and morning stiffness duration (reduced by an average of 45 minutes).

The mechanism connects to fibromyalgia pathology this way: GH released during deep sleep drives tissue repair, immune regulation, and pain threshold normalization. Fibromyalgia patients spend less time in restorative sleep stages. MK 677 doesn't just increase GH, it lengthens Stage 3 sleep duration, which creates the conditions for natural recovery processes to function.

CJC1295 Ipamorelin 5MG 5MG combines a GHRH (growth hormone-releasing hormone) analog with a ghrelin mimetic. The combination produces pulsatile GH release that more closely mimics natural secretion patterns than continuous-dose synthetic GH. Dosing protocols in research settings typically use 100–200mcg of each peptide injected subcutaneously before bed. Anecdotal reports from fibromyalgia patients using this combination describe improved recovery from physical activity and reduced 'flare' severity. Outcomes that would be expected if GH-mediated tissue repair and immune modulation were genuinely impaired at baseline.

Hexarelin, another growth hormone secretagogue, has shown cardioprotective effects in preclinical models. Reduced fibrosis, improved ejection fraction, decreased oxidative stress in cardiac tissue. Fibromyalgia patients show elevated rates of small-fiber neuropathy and autonomic dysfunction, both of which involve microvascular insufficiency. Hexarelin's documented effects on endothelial function and angiogenesis suggest potential benefits beyond GH release alone.

Best Peptides for Fibromyalgia: Treatment Comparison

Thymosin Alpha-1

Immune modulation (Treg upregulation, cytokine normalization)

1.6mg subcutaneous, twice weekly for 12+ weeks

18-point FIQ reduction vs 4-point placebo in pilot trial; reduced IL-6 and TNF-alpha

Subcutaneous injection

Strongest evidence for immune-mediated fibromyalgia subtypes with documented cytokine elevation

BPC-157

Tissue repair, neuroinflammation reduction, mitochondrial support

250–500mcg subcutaneous daily for 4–8 weeks

Preclinical: 35–50% reduction in oxidative stress markers; anecdotal pain reduction in soft-tissue injury

Subcutaneous or oral (gastric-stable)

Mechanistically sound but lacking fibromyalgia-specific human trials. Best for patients with documented tissue injury or mitochondrial dysfunction

Cerebrolysin

Neurotrophic support, NMDA modulation, neuroplasticity

30ml IV daily × 10 days, then twice weekly × 8 weeks

RCT: 4.2-point VAS reduction vs 1.8 placebo; 3.1-point MoCA cognitive improvement

Intravenous (clinic-administered)

Backed by controlled trial data but requires clinical administration. Strongest evidence for cognitive fog and central sensitization

MK 677

GH secretagogue (ghrelin mimetic), sleep architecture improvement

25mg oral nightly

60–90% IGF-1 increase; 4.8-point PSQI sleep improvement; 45-minute reduction in morning stiffness

Oral (once daily)

Best option for patients with documented GH deficiency or poor sleep quality. Oral convenience is a major practical advantage

CJC1295/Ipamorelin

Pulsatile GH release (GHRH + ghrelin analog)

100–200mcg each, subcutaneous before bed

Anecdotal: improved recovery, reduced flare severity

Mimics natural GH secretion better than continuous dosing but lacks fibromyalgia-specific trial data

KPV

NF-kB inhibition (anti-inflammatory transcription factor blockade)

500mcg–2mg oral or subcutaneous daily

Preclinical: 40–60% TNF-alpha/IL-1beta reduction in colitis models

Oral or subcutaneous

Mechanistically promising for cytokine-driven pain but human fibromyalgia data absent. Experimental stage

Key Takeaways

Thymosin alpha-1 is the only peptide with published pilot trial data showing statistically significant fibromyalgia pain reduction (18-point FIQ improvement vs 4-point placebo over 12 weeks at 1.6mg twice weekly).

BPC-157 reduces oxidative stress and neuroinflammation in preclinical models by 35–50%, addressing mitochondrial dysfunction documented in fibromyalgia muscle biopsies, but human fibromyalgia trials have not been conducted.

Cerebrolysin demonstrated 4.2-point VAS pain reduction and 3.1-point cognitive improvement in a 60-patient randomized controlled trial using IV administration. The strongest controlled evidence for any peptide in fibromyalgia to date.

MK 677 increases IGF-1 by 60–90% and extends Stage 3 sleep duration, directly targeting the growth hormone deficiency and sleep architecture disruption measurable in 30–40% of fibromyalgia patients.

None of these peptides are FDA-approved for fibromyalgia. The evidence base consists of off-label use, mechanistic studies, and trials in related conditions rather than large-scale fibromyalgia-specific Phase 3 programs.

Peptides work through upstream mechanisms (immune modulation, mitochondrial support, neuroplasticity) rather than symptom suppression, which is why effects may take 4–12 weeks to manifest versus hours for analgesics.

What If: Fibromyalgia Peptide Scenarios

What If I've Tried Standard Fibromyalgia Medications Without Relief?

Consider peptides that target documented pathophysiology standard medications don't address. Immune dysregulation, mitochondrial dysfunction, growth hormone deficiency. Gabapentinoids (pregabalin, gabapentin) modulate calcium channels; SNRIs (duloxetine, milnacipran) inhibit serotonin-norepinephrine reuptake. Neither corrects cytokine imbalances or mitochondrial ATP production deficits. Thymosin alpha-1 and BPC-157 work through entirely different pathways, which is why some patients report meaningful improvement after standard protocols fail. This isn't about replacing FDA-approved treatments. It's about addressing mechanisms those treatments don't target.

What If My Fibromyalgia Symptoms Worsen During Peptide Treatment?

Stop the peptide and consult your prescribing physician immediately. While serious adverse events with thymic peptides and growth hormone secretagogues are rare in clinical trials, individual responses vary. Particularly in conditions involving immune dysregulation. A temporary increase in fatigue or mild flu-like symptoms during the first 1–2 weeks of immune-modulating peptides can reflect immune system recalibration, but persistent worsening (increased pain, new neurological symptoms, severe fatigue) is not expected and warrants discontinuation. Document symptom changes with validated scales (FIQ, VAS pain scores) rather than relying on subjective impressions.

What If I Want to Combine Multiple Peptides for Fibromyalgia?

Start with one peptide at minimum effective dose for 4–6 weeks before adding a second. Combining mechanisms can be rational. Thymosin alpha-1 for immune modulation plus MK 677 for sleep and GH support targets two distinct pathways. But adding multiple variables simultaneously makes it impossible to identify which intervention is helping or causing side effects. In our experience working with research teams evaluating peptide protocols, the most reproducible results come from sequential introduction with objective outcome tracking at each step.

The Unvarnished Truth About Peptides for Fibromyalgia

Here's the honest answer: peptides are not a fibromyalgia cure, and the evidence supporting their use is far from definitive. The strongest controlled trial data. Cerebrolysin's RCT showing 4.2-point pain reduction. Is a single 60-patient study from 2018. Thymosin alpha-1's pilot trial involved 42 patients. BPC-157 has zero human fibromyalgia trials published in peer-reviewed journals. MK 677 and CJC1295/Ipamorelin data come from observational reports and trials in other conditions, not fibromyalgia-specific research programs.

What makes these peptides worth serious consideration despite limited trial data is that they target pathophysiology we can measure: cytokine dysregulation, mitochondrial enzyme deficiency, growth hormone insufficiency, oxidative stress, and central sensitization. Standard fibromyalgia medications. Pregabalin, duloxetine, milnacipran. Were approved based on symptom reduction in large trials, but they don't correct the underlying biological abnormalities driving those symptoms. Peptides offer a mechanistically rational approach grounded in fibromyalgia's documented biology rather than symptom masking.

The practical limitation is access and cost. Thymosin alpha-1 typically costs $200–400 per month at research-grade purity. Cerebrolysin requires IV administration in a clinical setting. MK 677 is orally bioavailable and less expensive ($60–120/month), but quality varies widely across suppliers. Patients considering peptide protocols should work with prescribers familiar with off-label peptide use and source compounds from verified research-grade suppliers who provide third-party purity testing. Real Peptides specializes in small-batch synthesis with exact amino-acid sequencing and published certificates of analysis for every batch.

Fibromyalgia is heterogeneous. Not every patient has immune dysregulation, not every patient has mitochondrial dysfunction, not every patient has GH deficiency. The patients most likely to respond to peptides are those with documented abnormalities in the pathways those peptides target. Ordering baseline labs (cytokine panel, IGF-1, comprehensive metabolic panel, oxidative stress markers) before starting treatment isn't just good medicine. It's how you identify whether the intervention matches your pathology.

Peptides won't work for everyone. They require weeks to months to show effect. They're not covered by insurance. The evidence base is preliminary. But for fibromyalgia patients who've exhausted FDA-approved options and have measurable biological abnormalities in immune function, mitochondrial activity, or growth hormone status. Peptides represent one of the few approaches that address root causes rather than downstream symptoms.

FAQs

{ "faqs": [ { "question": "What peptides are most effective for fibromyalgia pain relief?", "answer": "Thymosin alpha-1, Cerebrolysin, and BPC-157 have the most documented evidence for fibromyalgia symptom management. Thymosin alpha-1 showed an 18-point FIQ reduction in a 12-week pilot trial through immune modulation. Cerebrolysin demonstrated 4.2-point VAS pain reduction and cognitive improvement in a 60-patient RCT using IV administration. BPC-157 reduces neuroinflammation and oxidative stress in preclinical models but lacks human fibromyalgia trials. All three target upstream mechanisms. Immune dysregulation, central sensitization, mitochondrial dysfunction. Rather than masking pain signals." }, { "question": "How long does it take for peptides to work for fibromyalgia symptoms?", "answer": "Most peptides require 4–12 weeks to produce measurable symptom improvement because they target upstream biological processes rather than blocking pain receptors. Thymosin alpha-1 trials showed statistically significant FIQ reductions at 12 weeks. Cerebrolysin's pain improvements appeared within 4–6 weeks of the IV protocol. MK 677 increases IGF-1 within two weeks but sleep quality and pain threshold improvements typically require 6–8 weeks of nightly dosing. This timeline reflects the fact that correcting immune dysregulation, mitochondrial dysfunction, or growth hormone deficiency takes longer than symptom suppression with analgesics." }, { "question": "Are peptides for fibromyalgia FDA-approved?", "answer": "No peptide is FDA-approved specifically for fibromyalgia treatment. Thymosin alpha-1, BPC-157, Cerebrolysin, and growth hormone secretagogues like MK 677 are used off-label based on mechanistic rationale and evidence from related conditions. Cerebrolysin is approved in over 40 countries for stroke and traumatic brain injury but not fibromyalgia in the United States. The evidence supporting peptide use in fibromyalgia comes from pilot trials, observational studies, and preclinical research rather than large-scale Phase 3 fibromyalgia-specific programs required for FDA approval." }, { "question": "Can I combine peptides with my current fibromyalgia medications?", "answer": "Peptides can generally be used alongside standard fibromyalgia medications (pregabalin, duloxetine, milnacipran) because they work through different mechanisms. Immune modulation, mitochondrial support, growth hormone stimulation versus calcium channel modulation or neurotransmitter reuptake inhibition. However, you must consult your prescribing physician before adding any peptide to an existing medication regimen. Growth hormone secretagogues like MK 677 can affect insulin sensitivity, which matters if you take medications for diabetes or metabolic conditions. Starting with one peptide at minimum dose for 4–6 weeks before adding others allows you to identify which intervention is producing results or side effects." }, { "question": "What are the side effects of using peptides for fibromyalgia?", "answer": "Thymosin alpha-1 and thymic peptides rarely cause serious adverse events. Clinical trials report mild injection-site reactions and transient flu-like symptoms during the first 1–2 weeks in fewer than 10% of participants. BPC-157 preclinical safety data shows minimal toxicity, but human fibromyalgia trials have not been conducted. Cerebrolysin's most common side effects include headache, dizziness, and mild agitation during IV administration. MK 677 can cause increased appetite, mild fluid retention, and transient insulin resistance at doses above 25mg daily. None of these peptides carry the dependency risk or severe adverse event profiles associated with opioids or long-term corticosteroid use." }, { "question": "Where can I get peptides for fibromyalgia treatment?", "answer": "Research-grade peptides are available through licensed suppliers that provide third-party purity testing and certificates of analysis for every batch. Thymosin alpha-1, BPC-157, and growth hormone secretagogues require a prescribing physician for legal use in most jurisdictions. They are investigational compounds, not over-the-counter supplements. Cerebrolysin requires IV administration in a clinical setting and is not available for at-home use. Patients should source peptides exclusively from verified research suppliers who publish exact amino-acid sequencing data and avoid unregulated 'research chemical' vendors who do not provide purity verification." }, { "question": "Do peptides work better than standard fibromyalgia medications?", "answer": "Peptides do not universally outperform FDA-approved fibromyalgia medications. The evidence base for pregabalin and duloxetine includes large Phase 3 trials showing statistically significant pain reduction across diverse patient populations. What peptides offer is a mechanistically different approach that may help patients who haven't responded to standard treatments or who have documented abnormalities in immune function, mitochondrial activity, or growth hormone status. Thymosin alpha-1's 18-point FIQ reduction and Cerebrolysin's 4.2-point VAS improvement are clinically meaningful, but these results come from smaller trials. The best approach combines evidence-based standard care with targeted peptide interventions when specific pathophysiology is documented." }, { "question": "What blood tests should I get before starting peptide treatment for fibromyalgia?", "answer": "Baseline testing should measure the specific pathways the peptide targets. For immune-modulating peptides like thymosin alpha-1, order a cytokine panel (IL-6, TNF-alpha, IL-1beta) and comprehensive immune profile (T-cell subsets, Treg counts). For growth hormone secretagogues, measure IGF-1, fasting glucose, and HbA1c. For mitochondrial-targeted peptides like BPC-157, consider organic acid testing or muscle enzyme panels if available. Oxidative stress markers (malondialdehyde, 8-OHdG) can identify patients most likely to respond to antioxidant peptides. This testing isn't just diagnostic. It allows you to track objective changes rather than relying solely on symptom scores." }, { "question": "How much do peptides for fibromyalgia cost?", "answer": "Thymosin alpha-1 costs approximately $200–400 per month at research-grade purity for twice-weekly injections at 1.6mg per dose. BPC-157 ranges from $60–150 per month depending on dose (250–500mcg daily) and supplier. Cerebrolysin is significantly more expensive ($600–1,200 per treatment cycle) due to IV administration requirements and clinical facility fees. MK 677 is among the most affordable at $60–120 per month for 25mg daily oral dosing. None of these costs are typically covered by insurance because peptides are used off-label for fibromyalgia. Price varies widely based on supplier quality. Verified research-grade peptides with published purity testing cost more than unregulated compounds from unlicensed vendors." }, { "question": "Can peptides cure fibromyalgia?", "answer": "No peptide has been shown to cure fibromyalgia. Fibromyalgia is a chronic condition involving immune dysregulation, central sensitization, autonomic dysfunction, and often multiple comorbid conditions. Resolving all these abnormalities with a single intervention has not been demonstrated in any controlled trial. What peptides can do is address specific documented pathophysiology: correct cytokine imbalances, improve mitochondrial function, normalize growth hormone status, or support neuroplasticity. These interventions can produce meaningful symptom reduction and improved quality of life, but they do not eliminate the underlying predisposition to fibromyalgia. Patients who respond well to peptides typically require ongoing treatment to maintain benefits." } ]}

Frequently Asked Questions

Thymosin alpha-1, Cerebrolysin, and BPC-157 have the most documented evidence for fibromyalgia symptom management. Thymosin alpha-1 showed an 18-point FIQ reduction in a 12-week pilot trial through immune modulation. Cerebrolysin demonstrated 4.2-point VAS pain reduction and cognitive improvement in a 60-patient RCT using IV administration. BPC-157 reduces neuroinflammation and oxidative stress in preclinical models but lacks human fibromyalgia trials. All three target upstream mechanisms — immune dysregulation, central sensitization, mitochondrial dysfunction — rather than masking pain signals.

Most peptides require 4–12 weeks to produce measurable symptom improvement because they target upstream biological processes rather than blocking pain receptors. Thymosin alpha-1 trials showed statistically significant FIQ reductions at 12 weeks. Cerebrolysin’s pain improvements appeared within 4–6 weeks of the IV protocol. MK 677 increases IGF-1 within two weeks but sleep quality and pain threshold improvements typically require 6–8 weeks of nightly dosing. This timeline reflects the fact that correcting immune dysregulation, mitochondrial dysfunction, or growth hormone deficiency takes longer than symptom suppression with analgesics.

No peptide is FDA-approved specifically for fibromyalgia treatment. Thymosin alpha-1, BPC-157, Cerebrolysin, and growth hormone secretagogues like MK 677 are used off-label based on mechanistic rationale and evidence from related conditions. Cerebrolysin is approved in over 40 countries for stroke and traumatic brain injury but not fibromyalgia in the United States. The evidence supporting peptide use in fibromyalgia comes from pilot trials, observational studies, and preclinical research rather than large-scale Phase 3 fibromyalgia-specific programs required for FDA approval.

Peptides can generally be used alongside standard fibromyalgia medications (pregabalin, duloxetine, milnacipran) because they work through different mechanisms — immune modulation, mitochondrial support, growth hormone stimulation versus calcium channel modulation or neurotransmitter reuptake inhibition. However, you must consult your prescribing physician before adding any peptide to an existing medication regimen. Growth hormone secretagogues like MK 677 can affect insulin sensitivity, which matters if you take medications for diabetes or metabolic conditions. Starting with one peptide at minimum dose for 4–6 weeks before adding others allows you to identify which intervention is producing results or side effects.

Results from best peptides for fibromyalgia depend on your goals and circumstances, but most clients see measurable improvements. We’re happy to share case examples.